Seeking Alpha

Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just...

Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just 7% upside for the stock vs. double that for the rest of the pharmaceutical group (see Eli Lilly upgrade). "We see JNJ as lacking transformational pipeline opportunities." Shares -1.2% premarket.
Comments (1)
  • chopchop0
    , contributor
    Comments (3846) | Send Message
     
    This is literally right next to the comment concerning LLY where their "skepticism was proven wrong" Pardon me if I don't a $%*#$ about what Goldman thinks about JNJ LOL
    9 Oct 2012, 08:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs